01 August 2025
01 August 2025
Major pharma manufacturers have a 29 September deadline to adjust their drug prices relative to other developed countries.
Heavy investment into R&D for Dupixent鈥檚 successor meant earnings per share fell short of expectations.
Eli Lilly鈥檚 trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.
Tidmarsh will temporarily guide CBER鈥檚 regulatory activities while the FDA searches for a permanent department lead.
The addition of Zurzuvae is expected to diversify and increase the company's revenue base and cash flow.
The designation was based on the therapy鈥檚 novel mechanism and data showing its anti-tumour activity in B-cell malignancies.
The companies will work to advance ATB102 to treat inflammatory bowel disease.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
